KMB enters its July 21 earnings report with an unusual combination: a 15% rally over the past month, short interest near a multi-month high, and a Street that is quietly growing more constructive even as bears circle the input-cost story.
The short positioning is the most striking feature of the current setup. Short interest has climbed to 14.5% of the free float — a level that is high for a household-products name — and rose more than 14% over the past month alone. The week-on-week move is a more modest 2%, suggesting the build is steady rather than panicked. What makes this less alarming than it looks is the borrow market: availability is running at 227%, meaning more than two shares remain available to lend for every share currently borrowed. Cost to borrow is also easing, down roughly 13% over the past month to around 0.54% — near the low end of the past 30 days. Shorts are rebuilding their position, but the lending market is not under any strain. The ORTEX short score holds at 71.9, consistent and elevated, placing KMB in the bottom 7th percentile of its peer universe — a persistent signal that bears have not walked away from this name.
Options traders, by contrast, are not especially defensive heading into earnings. The put/call ratio is running at 0.56, only fractionally above its 20-day average of 0.54 and a z-score of just 0.73 — well within normal range. At its 52-week high the PCR touched 0.84, so the current read suggests options markets are not pricing elevated downside risk. That disconnect between active short positioning and relaxed options hedging is the clearest tension in the setup ahead of July 21.
The Street has turned more constructive after several months of cuts. Wells Fargo raised its target this week from $100 to $110 — though it kept its Equal-Weight rating, signaling a view that the re-rating has largely run its course. Piper Sandler lifted its target to $121 in June, maintaining Overweight. Both moves follow a wave of April cuts, when multiple firms trimmed targets into tariff and input-cost uncertainty; the arc is now reversing. The consensus mean target of $114.80 sits almost exactly at the current price of $114.74, which tells you the Street sees the stock as fairly valued after the run — not deeply discounted, not dangerously stretched. Valuation multiples confirm the re-rating: the P/E has expanded by about 1 full turn over 30 days to 14.1x, and EV/EBITDA has drifted to 11.3x. The forward EPS growth score ranks in the 74th percentile — KMB's strongest factor — while EPS momentum over both 30 and 90 days is near the bottom of the universe at 14 and 34 respectively. Bulls point to second-half acceleration from new product innovation and the KVUE consumer health portfolio addition. Bears argue the KVUE acquisition won't lift earnings until 2028 and that resin costs — roughly 25% of the cost-of-goods basket — remain a live threat, with an estimated $0.70–$0.80 EPS drag if current prices hold.
Among closest peers, PG rose 2.9% on the week and CL added 2.8%, broadly matching KMB's 4.5% weekly gain. REYN and CENT are the notable outliers, both down more than 3–4% on the week, which suggests the rally in household-products names is not uniform. CLX was essentially flat. KMB's relative strength this week is real, not just sector drift.
Recent earnings history offers a consistent pattern: the stock fell 1.2% the day after the May 2026 report and dropped 2.2% after the April 2026 print, though both recovered some ground within the five-day window. Neither reaction was large. With the mean analyst target sitting right at spot price and short interest near a 30-day high, the July 21 print becomes a test of whether the second-half acceleration thesis is credible enough to keep bears at bay — or whether elevated resin costs and North America volume softness give them fresh reason to press the position.
See the live data behind this article on ORTEX.
Open KMB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
